References
1. Subbiah RN, Gula LJ, Skanes AC, et al. Andersen-Tawil syndrome: Management challenges during pregnancy, labor, and delivery. J Cardiovasc Electrophysiol . 2008; 19(9):987-9
2. Fox DJ, Klein GJ, Hahn A, et al. Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome. Europace . 2008;10(8):1006-8.
3. Pellizzón OA, Kalaizich L, Ptácek LJ, et al. Flecainide Suppresses Bidirectional Ventricular Tachycardia and Reverses Tachycardia-Induced Cardiomyopathy in Andersen-Tawil Syndrome. J Cardiovasc Electrophysiol. 2007;19(1):95-7.
4. Anneken L, Baumann S, Vigneault P, et al. Estradiol regulates human QT-interval: Acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. Eur Heart J . 2016;37(7):640-50.
5. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of β-blocker therapy in congenital long- QT syndrome. Circulation . 2000;101(6):616-23.
6. Brembilla-perrot B, Amor M, Auque F, et al. Effect of flecainide on left ventricular ejection fraction. Eur Heart J.1987;8(7):754–61.
7. Van Ert HA, McCune EC, Orland KM, et al. Flecainide treats a novel KCNJ2 mutation associated with Andersen-Tawil syndrome. Hear Case Reports . 2017;3(2):151-154.
8. Hayashi H, Kawaguchi T, Horie M. Effect of Flecainide on T-Wave Alternans in Andersen-Tawil Syndrome. Ann Noninvasive Electrocardiol . 2014;19(4):383-6.
9. Bökenkamp R, Wilde AA, Schalij MJ, et al. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome. Hear Rhythm . 2007;4(4):508-11.
10. Janson CM, Poelzing S, Shah MJ. Combined inhibition of Na+ and Ca2+ channels: A novel paradigm for the treatment of incessant ventricular arrhythmias in Andersen-Tawil syndrome. Hear Rhythm . 2014;11(2):318-20.
11. Fernández M, Marín MDR, Fernández-Armenta J, et al. Response to flecainide test in Andersen-Tawil syndrome with incessant ventricular tachycardia. PACE - Pacing Clin Electrophysiol . 2018;41(4):429-432.